Evaluation, Treatment and Monitoring of Patients With a Known or Suspected Parasitic Infection
NCT00001645 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800
Last updated 2026-03-16
Summary
The purpose of this study is to evaluate, treat and follow patients with parasitic infections.
People with a known or suspected parasitic infection who are at least 1 year old may be enrolled. This study does not involve any experimental treatments.
Participants will have a physical examination and laboratory tests on blood, stool, or urine. Blood samples may be collected at regular intervals, but no more than 450 ml (15 ounces) of blood will be drawn from adults, and no more than 7 ml (1-1/2 teaspoons) per kg (2.2 pounds) of body weight from children, in any 6-week period. Other tests may include x-rays, electrocardiogram (EKG), or tissue biopsy (surgical removal of a small tissue sample), depending on the individual s condition.
Patients may be offered treatment or may be referred to another study that is more appropriate for the problem. Any treatment provided in this study will be according to standard medical practice for the patient s specific medical problem. Patients responses to treatment will be evaluated at regularly scheduled clinic visits. The length of time between visits and the total duration of the study for a given individual will be determined by the study doctor, based on that person s medical condition.
Conditions
- Malaria
- Intestinal Worms
- GI Protozoa
- Echiniococcus
- Strongyloides
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Thomas B Nutman, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 3 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-10-10
Countries
- United States
Study Locations
More Related Trials
-
Effect of Albendazole Dose on Clearance of Filarial Worms
NCT00339417 ·Status: COMPLETED ·Phase: PHASE2
-
Monitoring Drug Efficacy and Anthelmintic Resistance in Soil-transmitted Helminth Programs
NCT04177654 ·Status: COMPLETED
-
A Study of Co-infections of HIV-1 and Schistosoma Mansoni and Its Impact on Praziquantel Treatment Outcomes
NCT01541631 ·Status: UNKNOWN ·Phase: NA
-
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
NCT02032043 ·Status: COMPLETED
-
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
NCT01905436 ·Status: COMPLETED
-
Safety and Efficacy of IDA for Onchocerciasis
NCT04188301 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Drug Combinations Against Trichuris Trichiura
NCT01050452 ·Status: COMPLETED ·Phase: NA
-
Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression
NCT00507221 ·Status: COMPLETED ·Phase: NA
-
Health Benefits of Repeated Treatment in Pediatric Schistosomiasis
NCT01424410 ·Status: COMPLETED
-
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
NCT01975441 ·Status: COMPLETED ·Phase: PHASE2
-
Parasitism & COVID19 Vaccines: New Challenge.
NCT05185778 ·Status: NOT_YET_RECRUITING
-
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
NCT02078024 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Drug Combinations Against Schistosomiasis
NCT01050374 ·Status: COMPLETED ·Phase: NA
-
Evaluation of an AI-DP for STH Deworming Programs: a Study Protocol
NCT06055530 ·Status: UNKNOWN
-
Repeated Controlled Human Schistosoma Mansoni Infection
NCT05085470 ·Status: COMPLETED ·Phase: NA
-
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
NCT01903057 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology
NCT02878564 ·Status: COMPLETED ·Phase: PHASE4
-
Validation of INSPiRED Innovative Smart Diagnostic Devices for the Detection of Parasites Infections.
NCT04505046 ·Status: UNKNOWN
-
Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole
NCT02876146 ·Status: COMPLETED ·Phase: NA
-
Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana
NCT00463931 ·Status: COMPLETED
-
Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis
NCT01869465 ·Status: UNKNOWN ·Phase: NA
-
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
NCT06282315 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy of Drug Combinations Against Triple Infections
NCT01050517 ·Status: COMPLETED ·Phase: NA
-
Lymphatic Filariasis (LF) in Ivory Coast
NCT02974049 ·Status: COMPLETED ·Phase: NA
-
Schistosoma Mansoni Morbidity in Children Aged 1-5 Years
NCT01901484 ·Status: COMPLETED ·Phase: PHASE2